Check long-term safety and effectiveness of CF medicines
Part of Digestive system, Genetic & congenital, Lungs & breathing clinical trials.
This Phase 3 study looks at how well and how safely Vanzacaftor/Tezacaftor/Deutivacaftor works over the long term in people with cystic fibrosis who already took the study medicine before. It may help confirm the best long-term plan and spot important safety issues.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have finished the earlier study (the parent study) where you took the study drug (VX21-121-105).
- You must be able to join either Part A completion, or if you had a break in dosing, you did not stop forever and you completed the study visits through the last scheduled treatment visit.
- You cannot have certain serious liver conditions (including cirrhosis with portal hypertension or moderate/severe liver impairment) that increase risk.
- You must not have had an organ transplant, a blood-related transplant, or a past cancer.
- You must not have had a prior intolerance (bad reaction that led to stopping) to the study drug in the earlier study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an investigational drug called VX-581 in healthy volunteers to see how safe it is and how the body handles it. It is an early-phase trial, so it helps determine the right dose for future studies.
This study tests a new investigational medicine called VX-272 in healthy volunteers. Researchers want to check its safety and how it moves through the body, so you would not have the condition the medicine is being developed for.
This study looks at how well a highly effective cystic fibrosis (CF) medicine works in infants and young children, and what biological changes it causes. It may help families understand whether the medicine improves CF function and related measures early in life.
This study looks at how well CFTR-modulator medicines are working in people with cystic fibrosis, by checking specific “biomarkers” (measurable signals) in samples. Your care team may use the results to better understand how these medicines help, especially for certain CFTR changes.
This study tests how well a new tablet version of an experimental medicine (VX-581) is absorbed by the body. It may help researchers find the best way to give this medicine in the future.
This trial tests how well cystic fibrosis (CF) medicine works for you using an “n-of-1” approach, meaning you try treatments in a structured, repeated way to see what helps you most. It may help your care team choose the best option for your specific CF genetics and health status.
Hear when a new Cystic Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.